Antibody titres decline 3-month post-vaccination with BNT162b2

@article{Favresse2021AntibodyTD,
  title={Antibody titres decline 3-month post-vaccination with BNT162b2},
  author={Julien Favresse and Jean-Louis Bayart and François Mullier and Marc Elsen and Christine Eucher and Sandrine van Eeckhoudt and Tatiana Roy and Gr{\'e}goire Wieers and Christine Laurent and Jean Michel Dogn{\'e} and M{\'e}lanie Closset and Jonathan Douxfils},
  journal={Emerging Microbes \& Infections},
  year={2021},
  volume={10},
  pages={1495 - 1498}
}
ABSTRACT Several studies reported on the humoral response in subjects having received the BNT162b2 mRNA COVID-19 vaccine. However, data on the kinetics of antibodies 3 months post-vaccination are currently lacking and are important to drive the future vaccination strategy. The CRO-VAX HCP study is an ongoing multicentre, prospective and interventional study designed to assess the antibody response in a population of healthcare professionals who had received two doses of the BNT162b2 mRNA COVID… Expand

Figures from this paper

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers
TLDR
Whether this decrease in antibody levels correlates with an equivalent drop in the clinical effectiveness against the virus would require appropriate clinical studies. Expand
Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers
TLDR
Overall this study clearly shows antibody persistence at 6 months, albeit with a certain decline, and the use of this vaccine in addressing the COVID-19 pandemic is supported by the results that in turn open debate about the need for further boosts. Expand
Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
TLDR
Six months post-vaccination HCPs showed an antibody titer decrease of approximately 70%, yet, the titer was still one order of magnitude higher than that of seropositive individuals before vaccination, suggesting post- vaccination infection is possible even in the presence of a high anti-S serum antibodies titer. Expand
Decline of antibody titres three months after two doses of BNT162b2 in non-immunocompromised adults
TLDR
The decline of anti-RBD antibodies three months after the second dose of BNT162b2 is of concern because it raises the possibility of a short-lived humoral immunity after vaccination. Expand
Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
TLDR
The neutralizing antibodies (NAbs) in COVID-19 patients and in vaccinated individuals were measured and compared to six different SARS-CoV-2 serology assays and the agreement between the sVNT and pseudovirus VNT (pVNT) results was found to be excellent. Expand
Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination
TLDR
Immune response close after BNT162b2 vaccination is reduced in patients with IMID, but there is no significant difference at 5 months, and the measured reduction is related to age and the disease itself rather than treatments, with the exception of anti-CD20 drugs. Expand
Antibody maintenance 3 months after complete messenger RNA COVID-19 vaccination in haemodialysis patients
TLDR
This study aimed to determine anti-spike S1 receptor-binding domain (anti-S1-RBD) immunoglobulin G (IgG) presence and degree of decline 3 months after completing vaccination in centre haemodialysis patients with a greater risk of sudden acute respiratory syndrome coronavirus 2 infection. Expand
Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
TLDR
A potential difference in vaccine efficacy and vaccine effect length could possibly be present between subjects younger than 50 years and older participants, although in all cases, IgG levels were well above the level considered reactive by the test's manufacturer. Expand
Effect of the third dose of BNT162b2 vaccine in quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare workers
TLDR
The third dose applied after six months of the original BNT162b2 regimen provided a good humoral immune response by elevating the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers. Expand
SARS-CoV-2 specific T cell and humoral immune responses upon vaccination with BNT162b2
TLDR
This study demonstrated that both IgG-S and T cell responses were detected before acquiring sufficient levels of SARS-CoV-2 neutralizing antibodies, and these early immune responses are sustained for approximately six-ten weeks following the second vaccination dose. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 16 REFERENCES
Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
TLDR
Observed differences in vaccine responses between infection-naive and subjects with previous natural infection at t12 but not for a longer time are confirmed, and the influence of sex and age deserves further studies. Expand
Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)
TLDR
This study supports the concept that a single dose of BNT162b2 would be sufficient in previously infected individuals and raises the possibility that the optimal dose regimen in this population has not been clearly studied. Expand
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
TLDR
A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines. Expand
Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
TLDR
Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose. Expand
Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study
Objective To longitudinally evaluate the persistence of humoral immunity up to six months in a cohort of hospital employees with mild COVID-19. Methods We measured anti-RBD, -N andExpand
Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection
TLDR
Serological assays showed a clinically significant difference to detect past SARS-CoV-2 infection with total antibody assays presenting the highest positivity rates and the waning effect reported in several studies should be interpreted with caution. Expand
Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination
TLDR
A significant difference exists in post-mRNA COVID-19 vaccine immune response in baseline seronegative and seropositive subjects, which seems dependent on age and sex in ser onegative subjects, as well as on baseline anti-SARS-CoV-2 antibodies level in seropOSitive patients. Expand
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
TLDR
Results show that durable immunity against secondary COVID-19 disease is a possibility for most individuals, and assessing virus-specific immune memory over at least a 6-month period is likely necessary to ascertain the durability of immune memory to SARS-CoV-2. Expand
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
TLDR
It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided. Expand
COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough.
As COVID-19 cases resulting from infection with SARS-CoV-2 variants accumulate in the US and around the world, one question looms large: How well do the COVID-19 vaccines developed so far protectExpand
...
1
2
...